EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudie

Androgen Deficiency, Associations and Survival of Men With Stage 4 and 5 Chronic Kidney Disease: A Cohort Study

Neomal De Silva iD, Richard Quinton iD, Nipun Lakshitha De Silva iD, Channa N Jayasena iD, Bruna Barbar, Chris Boot, Rohana J Wright, Timothy W Shipley, N Suren Kanagasundaram

Clinical Endocrinology · 2025

DOI: 10.1111/cen.15146 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Endocrinology, 2025. Verfasst von Neomal De Silva und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology & Metabolism, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Royal Victoria Infirmary, Newcastle upon Tyne, UK. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Testosterone. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: This study was supported by Bayer, United Kingdom., Bayer, United Kingdom.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Anaemia is a key cause of morbidity in chronic kidney disease (CKD). Androgen deficiency (AD) in males can contribute to anaemia of all causes, including in CKD. We sought to examine the prevalence of AD in men with CKD, the extent to which it contributed to anaemia and whether it was independently associated with long‐term survival.

Methods

This cross‐sectional observational study was conducted among males aged 18 years and over with CKD stages 4 and 5. The study analysed morning blood samples with regard to their full blood count, urea and electrolytes, albumin, lipids, testosterone (T) and sex hormone binding globulin, with calculation of free testosterone by mass action equation. Mortality data were obtained 15 years later for survival analysis.

Results

Among 322 patients with a mean age of 63 years, the overall prevalence of AD was 68.9%. There was a statistically significant negative correlation between erythropoiesis stimulating agent (ESA) dose and testosterone concentrations (Pearson correlation −0.193, p = 0.05). There was a positive correlation between haemoglobin (Hb) and free testosterone level among patients not on ESA therapy (Pearson correlation 0.331, p < 0.001). Kaplan‐Meier plots showed p < 0.001 on log‐rank analysis, indicating that AD was significantly associated with worse survival. However, in Cox regression analysis, free testosterone was not associated with survival (95% CI for free testosterone 0.997–1.000).

Conclusions

AD is highly prevalent among this population, and increases further with older age and more severe CKD warranting haemodialysis. Association of lower Hb and higher ESA dose with lower T concentration might be causative, which has important pharmaco‐economic as well as clinical implications. Lower survival in men with low T, more likely reflects overall poor health rather than causation. A properly constituted randomised controlled study evaluating the effect of native T replacement is warranted in men with CKD and AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicTestosteroneHumansMaleMiddle AgedCross-Sectional StudiesAgedAndrogensAnemiaCohort StudiesAdultPrevalence

Stichwörter der Autor:innen

anaemiaandrogenchronic kidney diseasedialysiserythropoiesishaemoglobinhypogonadismmortalitytestosterone

Substanzen

TestosteroneAndrogens

Autor:innen und Institutionen

  • Department of Endocrinology & Metabolism, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
  • Translational & Clinical Research Institute, University of Newcastle, Newcastle upon Tyne, UK.
  • Department of Metabolism, Digestion & Reproduction, Imperial College London, London, UK.
  • Department of Clinical Sciences, Faculty of Medicine, General Sir John Kotelawala Defence University, Rathmalana, Sri Lanka.
  • Department of Laboratory Medicine, Newcastle-upon-Tyne Hospitals NHS Foundation Trust Freeman Hospital, Newcastle upon Tyne, UK.
  • Edinburgh Centre for Endocrinology & Diabetes, NHS Lothian, St John's Hospital, Livingston, UK.

ORCID-Profile: Neomal De Silva, Richard Quinton, Nipun Lakshitha De Silva, Channa N Jayasena

Förderung

  • This study was supported by Bayer, United Kingdom.
  • Bayer, United Kingdom

Zitieren

APA

De Silva, N., Quinton, R., De Silva, N. L., Jayasena, C. N., Barbar, B., Boot, C., Wright, R. J., Shipley, T. W., & Kanagasundaram, N. S. (2025). Androgen Deficiency, Associations and Survival of Men With Stage 4 and 5 Chronic Kidney Disease: A Cohort Study. Clinical Endocrinology. https://doi.org/10.1111/cen.15146

Vancouver

De Silva N, Quinton R, De Silva NL, Jayasena CN, Barbar B, Boot C, et al. Androgen Deficiency, Associations and Survival of Men With Stage 4 and 5 Chronic Kidney Disease: A Cohort Study. Clinical Endocrinology. 2025. doi:10.1111/cen.15146

BibTeX
@article{DeSilva2025,
  author = {De Silva, Neomal and Quinton, Richard and De Silva, Nipun Lakshitha and Jayasena, Channa N and Barbar, Bruna and Boot, Chris and Wright, Rohana J and Shipley, Timothy W and Kanagasundaram, N Suren},
  title = {Androgen Deficiency, Associations and Survival of Men With Stage 4 and 5 Chronic Kidney Disease: A Cohort Study},
  journal = {Clinical Endocrinology},
  year = {2025},
  doi = {10.1111/cen.15146}
}
Kostenlos starten →